Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive

Maintenance: Tuesday, 5.7.2016, 07:00-08:00

Maintenance work on ZORA and JDB on Tuesday, 5th July, 07h00-08h00. During this time there will be a brief unavailability for about 1 hour. Please be patient.

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-28007

Finckh, A; Ciurea, A; Brulhart, L; Möller, B; Walker, U A; Courvoisier, D; Kyburz, D; Dudler, J; Gabay, C (2010). Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent? Annals of the Rheumatic Diseases, 69(2):387-393.

View at publisher


BACKGROUND: Rheumatoid arthritis (RA) patients with an inadequate response to TNF inhibitors (aTNF) may switch to an alternative aTNF or start a treatment from a different class, such as rituximab (RTX). It remains unclear in which clinical settings these therapeutic strategies offer most benefit. OBJECTIVE: To analyze the effectiveness of RTX versus alternative aTNFs on RA disease activity in different subgroups of patients. METHODS: This is a prospective cohort study of RA patients who discontinued at least one aTNF and subsequently received either RTX or an alternative aTNF, nested within the Swiss RA registry (SCQM-RA). The primary outcome, longitudinal improvement in DAS28, was analysed using multivariate regression models for longitudinal data and adjusted for potential confounders. RESULTS: Of the 318 RA patients included; 155 received RTX and 163 received an alternative aTNF. The relative benefit of RTX varied with the type of prior aTNF failure: when the motive for switching was ineffectiveness to previous aTNFs, the longitudinal improvement in DAS28 was significantly better with RTX than alternative aTNF (p = 0.03; at 6 months, -1.34 (95% CI: -1.54; -1.15) versus -0.93 (95% CI: -1.28; -0.59) respectively). When the motive for switching was other causes, the longitudinal improvement in DAS28 was similar between RTX and alternative aTNFs (p =0.40). These results were not significantly modified by the number of previous aTNF failures, the type of aTNF switches, or the presence of DMARD co-therapy. CONCLUSION: This observational study suggests that RTX is more effective than switching to an alternative aTNF in RA patients who stopped a previous aTNF treatment because of ineffectiveness.


71 citations in Web of Science®
88 citations in Scopus®
Google Scholar™



31 downloads since deposited on 26 Jan 2010
8 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine
Dewey Decimal Classification:610 Medicine & health
Date:February 2010
Deposited On:26 Jan 2010 11:40
Last Modified:05 Apr 2016 13:47
Publisher:BMJ Publishing Group
Publisher DOI:10.1136/ard.2008.105064
PubMed ID:19416802

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page